MedTrace Logo

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

NCT06193148 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-12-12

No results posted yet for this study

Summary

To evaluate the effect of Jaktinib Hydrochloride Tablets on QT/QTc interval in healthy subjects after a single oral administration.

Conditions

  • Healthy Participants

Interventions

DRUG

Jaktinib

Participants will receive Jaktinib orally for single dose

DRUG

Placebo

Participants will receive Placebo orally for single dose

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • LiYan Miao · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-19
Primary Completion
2024-06-18
Completion
2024-06-18

Countries

  • China

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06193148 on ClinicalTrials.gov